Josh Hammer
Newsweek Senior Editor-at-Large And Host,
"The Josh Hammer Show"

For weeks now, Democrats and their corporate media lapdogs have been trying to derail the nomination of Pete Hegseth, President Donald Trump's inspired pick for secretary of defense. Their tactics have been just as loathsome as they have been eerily reminiscent: The whole operation looks like a rerunning of the discredited Brett Kavanaugh playbook, which leftists deployed back in 2018 to try and tar and feather Trump's second Supreme Court pick as some sort of criminal gang rapist. The Left's tossing out of five millennia of civilizational norms pertaining to due process and innocence until proven guilty was nothing if not eye-opening; for many of us, it was a true "red pill" moment. Thankfully, the Kavanaugh operation failed—albeit barely, and not with much room to spare.

Six years later, it is imperative that the Hegseth operation similarly fails. As I explained in a Daily Mail piece this past weekend, there is now much more at stake than Hegseth's future helming the bloated and byzantine Pentagon apparatus.

First, it is crucial that the Kavanaugh smear campaign tactics—which have been replicated almost entirely, right up to an implausible rape allegation and a recent entirely unsourced NBC News piece about his alleged drinking problems—fail once again. These bully tactics can never, ever succeed. For Democrats and their corporate media allies to succeed against Hegseth where they failed against Kavanaugh is to essentially permit an ever-looming threat of an oversize heckler's veto that is capable of nuking any Republican president's high-profile nomination. It is to reward the lowest, basest type of gutter politics that exists. American politics simply cannot exist in such a state—it is entirely unsustainable.

Second, it is equally crucial that President Trump not let his myriad enemies derail his agenda—and thereby set the tone—before his second term has even started. During Trump's first term, he was constantly undermined and subverted by an array of hostile forces—very much including those within his own party and even within his own administration. If Trump wants to prove to the critics and skeptics that he has learned the right lessons from his shortcomings last time, he must reenter the Oval Office on Jan. 20 with swagger and success—boasting both the optics of a winner as well as the transition period track record of someone who has already won. That means getting his major picks, such as his secretary of defense, on track for quick Senate confirmation. This is doubly true following the premature withdrawal of Matt Gaetz from consideration as U.S. attorney general.

Trump has ambitious plans for his second term. He has no time to waste—he has to hit the ground running. Right now, that means getting Cabinet picks like Pete Hegseth across the finish line.

To keep up with all my media hits and other writings, make sure to follow me on Twitter/X, Instagram, and Facebook. You can listen to all episodes of "The Josh Hammer Show" at the Newsweek website or on Apple, Spotify, or wherever you get your podcasts—as well as on select radio stations across the country. I also have a second show, "America on Trial with Josh Hammer," with The First; you can subscribe and listen on Apple, Spotify, or wherever you get your podcasts. Make sure to also check out my Subtext chat, which you can read all about and sign up for here.

Our highlighted Newsweek op-eds this week include selections from Max Eden and yours truly, Rep. Andy Biggs (R-Ariz.), Joey Jones, Asaf Romirowsky, and Paul du Quenoy.

Have a great rest of your week, everyone. We will be back in your inbox next Wednesday!

Anna Moneymaker/Getty Images
In Transgender Case, Can SCOTUS Cut to the Moral Heart of the Issue?

On Wednesday, the Supreme Court heard oral argument in this term's marquee case, United States v. Skrmetti.

The case, out of Tennessee, nominally involves a state law banning minors' use of puberty blockers and cross-sex hormones for purposes of so-called gender-affirming care—which, stripped of all euphemism, means genital mutilation and chemical castration. And the justices will indeed have to resolve the narrow legal question before them in this case: namely, whether or not Tennessee's commonsense protection of vulnerable youth from the predations of the billion-dollar transgender industry offends the 14th Amendment's injunction that no state "deny to any person within its jurisdiction the equal protection of the laws."

The straightforward legal answer is that it plainly does not. Fatuous arguments this week from the U.S. solicitor general and American Civil Liberties Union advocate aside, one simply cannot divorce the issue of medical treatment from the issue of medical purpose. Consider the case of fentanyl. There are legitimate purposes for small amounts of fentanyl, which can be used as a painkiller in a contained hospital setting. There are also myriad illegitimate purposes for fentanyl, as anyone remotely familiar with America's depressing drug overdose crisis can sadly attest. So too can a reasonable person distinguish between testosterone therapy for an adolescent boy with delayed puberty, on the one hand, and testosterone therapy for an adolescent girl with gender dysphoria, on the other hand.

Listen to the latest episode of
The Josh Hammer Show Here

Oleg Nikishin/Getty Images
DEI Is Unconstitutional
Read More
Andrew Harnik/Getty Images
Rep. Biggs: GOP Must Stand by Trump's Cabinet Picks
Read More
I'm a Veteran of Iraq and Afghanistan. Pete Hegseth Is the Secretary of Defense We Need
Read More
Amir Levy/Getty Images
Palestinians Are Facing a New Reality With Donald Trump in Power
Read More
Mandel NGAN/AFP/Getty Images
After Hunter Pardon, Nothing Stands in the Way of Trump Jan. 6 Pardons
Read More

Newsweek Site     |     See All Newsletters

Contact Us

Please send your feedback and ideas to j.hammer@newsweek.com

Digital Subscription

  • Unlimited access to Newsweek.com
  • Ad free Newsweek.com experience
  • iOS and Android app access
  • All newsletters + podcasts

Yearly $49